The independent source for health policy research, polling, and news.
KFF’s policy research provides facts and analysis on a wide range of policy issues and public programs.
KFF designs, conducts and analyzes original public opinion and survey research on Americans’ attitudes, knowledge, and experiences with the health care system to help amplify the public’s voice in major national debates.
KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the organization’s core operating programs.
This issue brief provides an overview of the Medicare Part D prescription drug benefit plan landscape for 2020, with a focus on stand-alone drug plans, the largest segment of the Part D market. It includes national and state-level data on plan availability, premiums, benefit design, cost sharing, information about premium-free plans for low-income beneficiaries, and information about the national Part D plans available in 2020.
Community health centers are a national network of safety-net primary care providers serving low-income, medically underserved communities. Based on findings from a national survey of health centers, this brief examines how the pandemic has affected health center patients and services as well as the ongoing challenges health centers and their patients face.
This brief reviews some of the possible actions of the incoming Trump administration and new Congress based on campaign statements, policies implemented by the first Trump administration, and proposals forwarded by allied conservative think tanks and antiabortion advocacy groups.
In this Axios column, Drew Altman looks beyond Medicare to what’s at stake for employers and workers in the debate about the government negotiating drug prices.
The $21.60 increase in 2022 is the largest in dollar terms since the start of the program, even though premiums have risen faster in percentage terms on three other occasions in the last 20 years
With federal regulators seeking public input on the potential benefits, costs, and implementation considerations of requiring private health insurance plans to cover over-the-counter preventive products without a prescription, a new KFF post explores the issues relevant to covering over-the-counter contraceptives. These contraceptives include Opill, the first daily oral contraceptive pill to receive FDA approval for over-the-counter availability. The analysis draws on the lessons learned from KFF staff interviews with more than 80 key players nationally…
More than 18 months into the COVID-19 pandemic, state Medicaid programs around the country continue to reshape policy in response to the public health emergency and at the same time advance broader initiatives and priorities, including efforts to address the social determinants of health and health equity, finds a new KFF survey. The 21st annual KFF survey of Medicaid directors in states and the District of Columbia highlights policies in place and changes implemented or…
This Health Policy 101 chapter explores the federal government’s role in health policy for the fragmented U.S. health care system. It examines the impact of the three federal branches and goes into further detail about the Department of Health and Human Services structure and the major congressional committees dealing with health care. It also briefly outlines the federal budgetary and regulatory process.
In 2020, only 25% of people who could benefit from pre-exposure prophylaxis (PrEP), a medication that reduces the risk of acquiring HIV, were prescribed it. Using telehealth to provide PrEP, “tele-PrEP,” is a new approach that shows potential for expanding access to PrEP use in the United States that predates the COVID-19 pandemic. A new KFF analysis takes a deep dive into the tele-PrEP landscape, from the types of providers offering the service to the…
The question of what would happen when a new, expensive prescription drug comes to market for a disease like Alzheimer’s that afflicts millions of people has loomed large in discussions over drug prices in the U.S. This brief analyzes the cost implications for Medicare and beneficiaries associated with Biogen's new FDA-approved Alzheimer's drug, which will cost $56,000 per year.
© 2026 KFF